Human Metabolome Technologies（6090）株式概要バイオテクノロジー企業であるヒューマン・メタボローム・テクノロジーズ株式会社は、日本で創薬、診断、食品製造のためのメタボロミクス技術とソリューションを開発しています。 詳細6090 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績2/6財務の健全性6/6配当金2/6リスク分析利益率(9%)は昨年より低い(21.3%) 意味のある時価総額がありません ( ¥3B )3.05%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見る6090 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW484,467 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA484,467 investors already sharing narrativesYour Fair ValueJP¥Current PriceJP¥591.005.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-359m2b2016201920222025202620282031Revenue JP¥1.7bEarnings JP¥151.8mAdvancedSet Fair ValueView all narrativesHuman Metabolome Technologies, Inc. 競合他社atectSymbol: TSE:4241Market cap: JP¥2.7bPrecision System ScienceSymbol: TSE:7707Market cap: JP¥5.5bCellSourceSymbol: TSE:4880Market cap: JP¥6.1bWDB cocoSymbol: TSE:7079Market cap: JP¥6.2b価格と性能株価の高値、安値、推移の概要Human Metabolome Technologies過去の株価現在の株価JP¥591.0052週高値JP¥794.0052週安値JP¥570.00ベータ-0.0571ヶ月の変化-2.96%3ヶ月変化-14.35%1年変化-24.13%3年間の変化-18.71%5年間の変化-27.66%IPOからの変化-79.20%最新ニュースUpcoming Dividend • Jun 22Upcoming dividend of JP¥18.00 per shareEligible shareholders must have bought the stock before 29 June 2026. Payment date: 04 September 2026. Payout ratio is a comfortable 73% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.9%). Lower than average of industry peers (3.9%).お知らせ • Jun 13Human Metabolome Technologies, Inc. to Report Fiscal Year 2026 Results on Aug 07, 2026Human Metabolome Technologies, Inc. announced that they will report fiscal year 2026 results on Aug 07, 2026Reported Earnings • May 17Third quarter 2026 earnings released: EPS: JP¥21.76 (vs JP¥35.84 in 3Q 2025)Third quarter 2026 results: EPS: JP¥21.76 (down from JP¥35.84 in 3Q 2025). Revenue: JP¥448.0m (down 23% from 3Q 2025). Net income: JP¥122.0m (down 42% from 3Q 2025). Profit margin: 27% (down from 36% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.New Risk • Feb 16New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Dividend per share is over 5x cash flows per share. Dividend yield: 2.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Dividend is not well covered by cash flows (dividend per share is over 5x cash flows per share). Market cap is less than US$100m (JP¥4.28b market cap, or US$27.9m).Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥24.79 (vs JP¥21.63 in 2Q 2025)Second quarter 2026 results: EPS: JP¥24.79 (up from JP¥21.63 in 2Q 2025). Revenue: JP¥467.0m (up 14% from 2Q 2025). Net income: JP¥140.0m (up 9.4% from 2Q 2025). Profit margin: 30% (down from 31% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.Declared Dividend • Feb 14Dividend of JP¥18.00 announcedShareholders will receive a dividend of JP¥18.00. Ex-date: 29th June 2026 Payment date: 4th September 2026 Dividend yield will be 2.5%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 27% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.最新情報をもっと見るRecent updatesUpcoming Dividend • Jun 22Upcoming dividend of JP¥18.00 per shareEligible shareholders must have bought the stock before 29 June 2026. Payment date: 04 September 2026. Payout ratio is a comfortable 73% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.9%). Lower than average of industry peers (3.9%).お知らせ • Jun 13Human Metabolome Technologies, Inc. to Report Fiscal Year 2026 Results on Aug 07, 2026Human Metabolome Technologies, Inc. announced that they will report fiscal year 2026 results on Aug 07, 2026Reported Earnings • May 17Third quarter 2026 earnings released: EPS: JP¥21.76 (vs JP¥35.84 in 3Q 2025)Third quarter 2026 results: EPS: JP¥21.76 (down from JP¥35.84 in 3Q 2025). Revenue: JP¥448.0m (down 23% from 3Q 2025). Net income: JP¥122.0m (down 42% from 3Q 2025). Profit margin: 27% (down from 36% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.New Risk • Feb 16New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Dividend per share is over 5x cash flows per share. Dividend yield: 2.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Dividend is not well covered by cash flows (dividend per share is over 5x cash flows per share). Market cap is less than US$100m (JP¥4.28b market cap, or US$27.9m).Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥24.79 (vs JP¥21.63 in 2Q 2025)Second quarter 2026 results: EPS: JP¥24.79 (up from JP¥21.63 in 2Q 2025). Revenue: JP¥467.0m (up 14% from 2Q 2025). Net income: JP¥140.0m (up 9.4% from 2Q 2025). Profit margin: 30% (down from 31% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.Declared Dividend • Feb 14Dividend of JP¥18.00 announcedShareholders will receive a dividend of JP¥18.00. Ex-date: 29th June 2026 Payment date: 4th September 2026 Dividend yield will be 2.5%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 27% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Feb 12Human Metabolome Technologies, Inc. (TSE:6090) announces an Equity Buyback for 25,000 shares, representing 4.44% for ¥200 million.Human Metabolome Technologies, Inc. (TSE:6090) announces a share repurchase program. Under the program, the company will repurchase up to 25,000 shares, representing 4.44% of its issued share capital, for ¥200 million. The purpose of the program is to improve shareholder returns and capital efficiency. The program will expire on December 31, 2026. As of December 31, 2025, the company had 5,627,579 shares in issue (excluding treasury stock and 292,218 shares in treasury.お知らせ • Nov 29Human Metabolome Technologies, Inc. to Report Q2, 2026 Results on Feb 12, 2026Human Metabolome Technologies, Inc. announced that they will report Q2, 2026 results on Feb 12, 2026New Risk • Nov 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (JP¥3.74b market cap, or US$24.2m).Reported Earnings • Nov 15First quarter 2026 earnings released: JP¥17.08 loss per share (vs JP¥5.92 loss in 1Q 2025)First quarter 2026 results: JP¥17.08 loss per share (further deteriorated from JP¥5.92 loss in 1Q 2025). Revenue: JP¥192.0m (down 30% from 1Q 2025). Net loss: JP¥97.0m (loss widened 177% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 4% per year.お知らせ • Oct 02Human Metabolome Technologies, Inc. to Report Q1, 2026 Results on Nov 12, 2025Human Metabolome Technologies, Inc. announced that they will report Q1, 2026 results on Nov 12, 2025分析記事 • Aug 16We Think That There Are Some Issues For Human Metabolome Technologies (TSE:6090) Beyond Its Promising EarningsHuman Metabolome Technologies, Inc.'s ( TSE:6090 ) healthy profit numbers didn't contain any surprises for investors...Reported Earnings • Aug 10Full year 2025 earnings released: EPS: JP¥43.59 (vs JP¥41.10 in FY 2024)Full year 2025 results: EPS: JP¥43.59 (up from JP¥41.10 in FY 2024). Revenue: JP¥1.46b (up 8.2% from FY 2024). Net income: JP¥256.0m (up 5.3% from FY 2024). Profit margin: 18% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year.お知らせ • Aug 08Human Metabolome Technologies, Inc., Annual General Meeting, Sep 19, 2025Human Metabolome Technologies, Inc., Annual General Meeting, Sep 19, 2025.New Risk • Jul 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Market cap is less than US$100m (JP¥4.36b market cap, or US$29.3m).Upcoming Dividend • Jun 20Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Japanese dividend payers (4.0%). Lower than average of industry peers (3.0%).お知らせ • Jun 07Human Metabolome Technologies, Inc. to Report Fiscal Year 2025 Results on Aug 08, 2025Human Metabolome Technologies, Inc. announced that they will report fiscal year 2025 results on Aug 08, 2025Reported Earnings • May 19Third quarter 2025 earnings released: EPS: JP¥35.84 (vs JP¥26.54 in 3Q 2024)Third quarter 2025 results: EPS: JP¥35.84 (up from JP¥26.54 in 3Q 2024). Revenue: JP¥582.0m (up 21% from 3Q 2024). Net income: JP¥211.0m (up 34% from 3Q 2024). Profit margin: 36% (up from 33% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year.分析記事 • Apr 14Why Investors Shouldn't Be Surprised By Human Metabolome Technologies, Inc.'s (TSE:6090) P/EHuman Metabolome Technologies, Inc.'s ( TSE:6090 ) price-to-earnings (or "P/E") ratio of 15x might make it look like a...お知らせ • Mar 01Human Metabolome Technologies, Inc. to Report Q3, 2025 Results on May 14, 2025Human Metabolome Technologies, Inc. announced that they will report Q3, 2025 results on May 14, 2025Declared Dividend • Feb 15Dividend of JP¥15.00 announcedShareholders will receive a dividend of JP¥15.00. Ex-date: 27th June 2025 Payment date: 5th September 2025 Dividend yield will be 2.3%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 38% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Feb 13Human Metabolome Technologies, Inc. (TSE:6090) announces an Equity Buyback for 130,000 shares, representing 2.2% for ¥100 million.Human Metabolome Technologies, Inc. (TSE:6090) announces a share repurchase program. Under the program, the company will repurchase up to 130,000 shares, representing 2.2% of its issued share capital, for ¥100 million. The purpose of the program is to improve shareholder returns and capital efficiency. The program will expire on December 31, 2025. As of December 31, 2024, the company had 5,919,653 shares in issue (excluding treasury stock and 144 shares in treasury.お知らせ • Jan 17Human Metabolome Technologies, Inc. to Report Q2, 2025 Results on Feb 13, 2025Human Metabolome Technologies, Inc. announced that they will report Q2, 2025 results on Feb 13, 2025Board Change • Oct 07Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Natsukari Hajime was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Oct 03Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole PictureThe subdued market reaction suggests that Human Metabolome Technologies, Inc.'s ( TSE:6090 ) recent earnings didn't...お知らせ • Oct 02Human Metabolome Technologies, Inc. to Report Q1, 2025 Results on Nov 13, 2024Human Metabolome Technologies, Inc. announced that they will report Q1, 2025 results on Nov 13, 2024お知らせ • Aug 09Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024.分析記事 • Aug 06Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The MarketWhen close to half the companies in Japan have price-to-earnings ratios (or "P/E's") above 14x, you may consider Human...Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to JP¥511, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total loss to shareholders of 32% over the past three years.Buy Or Sell Opportunity • Aug 05Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to JP¥511. The fair value is estimated to be JP¥639, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Meanwhile, the company has become profitable.Upcoming Dividend • Jun 20Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 27 June 2024. Payment date: 09 September 2024. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (2.6%).分析記事 • Jun 07Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00Human Metabolome Technologies, Inc.'s ( TSE:6090 ) dividend will be increasing from last year's payment of the same...お知らせ • Jun 06Human Metabolome Technologies, Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024Human Metabolome Technologies, Inc. announced that they will report fiscal year 2024 results on Aug 09, 2024分析記事 • May 22Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00Human Metabolome Technologies, Inc. ( TSE:6090 ) has announced that it will be increasing its dividend from last year's...Reported Earnings • May 21Third quarter 2024 earnings released: EPS: JP¥26.54 (vs JP¥26.07 in 3Q 2023)Third quarter 2024 results: EPS: JP¥26.54 (up from JP¥26.07 in 3Q 2023). Revenue: JP¥483.0m (up 3.9% from 3Q 2023). Net income: JP¥157.0m (up 1.9% from 3Q 2023). Profit margin: 33% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.分析記事 • Apr 06Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last YearThe board of Human Metabolome Technologies, Inc. ( TSE:6090 ) has announced that it will be paying its dividend of...お知らせ • Mar 28Human Metabolome Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024Human Metabolome Technologies, Inc. announced that they will report Q3, 2024 results on May 15, 2024分析記事 • Mar 23Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00The board of Human Metabolome Technologies, Inc. ( TSE:6090 ) has announced that it will be paying its dividend of...分析記事 • Feb 26Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00The board of Human Metabolome Technologies, Inc. ( TSE:6090 ) has announced that it will be paying its dividend of...Reported Earnings • Feb 17Second quarter 2024 earnings released: EPS: JP¥18.43 (vs JP¥15.41 in 2Q 2023)Second quarter 2024 results: EPS: JP¥18.43 (up from JP¥15.41 in 2Q 2023). Revenue: JP¥397.0m (up 14% from 2Q 2023). Net income: JP¥109.0m (up 20% from 2Q 2023). Profit margin: 28% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Declared Dividend • Feb 16Dividend of JP¥15.00 announcedShareholders will receive a dividend of JP¥15.00. Ex-date: 27th June 2024 Payment date: 9th September 2024 Dividend yield will be 2.3%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is covered by both earnings (22% earnings payout ratio) and cash flows (53% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 71% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.お知らせ • Nov 27Human Metabolome Technologies, Inc. to Report Q2, 2024 Results on Feb 14, 2024Human Metabolome Technologies, Inc. announced that they will report Q2, 2024 results on Feb 14, 2024Reported Earnings • Nov 12First quarter 2024 earnings released: JP¥6.43 loss per share (vs JP¥2.88 loss in 1Q 2023)First quarter 2024 results: JP¥6.43 loss per share (further deteriorated from JP¥2.88 loss in 1Q 2023). Revenue: JP¥235.0m (down 10% from 1Q 2023). Net loss: JP¥38.0m (loss widened 124% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Sep 28Human Metabolome Technologies, Inc. to Report Q1, 2024 Final Results on Nov 10, 2023Human Metabolome Technologies, Inc. announced that they will report Q1, 2024 final results on Nov 10, 2023New Risk • Aug 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 47% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Market cap is less than US$100m (JP¥4.29b market cap, or US$29.5m).Reported Earnings • Aug 12Full year 2023 earnings released: EPS: JP¥48.27 (vs JP¥45.25 in FY 2022)Full year 2023 results: EPS: JP¥48.27 (up from JP¥45.25 in FY 2022). Revenue: JP¥1.30b (up 6.2% from FY 2022). Net income: JP¥285.0m (up 6.7% from FY 2022). Profit margin: 22% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.お知らせ • Aug 12Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023.お知らせ • Jun 03Human Metabolome Technologies, Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023Human Metabolome Technologies, Inc. announced that they will report fiscal year 2023 results on Aug 10, 2023Reported Earnings • May 17Third quarter 2023 earnings released: EPS: JP¥26.07 (vs JP¥33.73 in 3Q 2022)Third quarter 2023 results: EPS: JP¥26.07 (down from JP¥33.73 in 3Q 2022). Revenue: JP¥465.0m (down 2.5% from 3Q 2022). Net income: JP¥154.0m (down 23% from 3Q 2022). Profit margin: 33% (down from 42% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 18Second quarter 2023 earnings released: EPS: JP¥15.41 (vs JP¥22.03 in 2Q 2022)Second quarter 2023 results: EPS: JP¥15.41 (down from JP¥22.03 in 2Q 2022). Revenue: JP¥348.0m (down 3.3% from 2Q 2022). Net income: JP¥91.0m (down 30% from 2Q 2022). Profit margin: 26% (down from 36% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Dec 24Human Metabolome Technologies, Inc. to Report Q2, 2023 Results on Feb 14, 2023Human Metabolome Technologies, Inc. announced that they will report Q2, 2023 results on Feb 14, 2023Buying Opportunity • Dec 20Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be JP¥833, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last year. Meanwhile, the company has become profitable.Reported Earnings • Nov 16First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)First quarter 2023 results: JP¥2.88 loss per share (improved from JP¥8.14 loss in 1Q 2022). Revenue: JP¥262.0m (up 51% from 1Q 2022). Net loss: JP¥17.0m (loss narrowed 65% from 1Q 2022).Reported Earnings • Nov 13First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)First quarter 2023 results: JP¥2.88 loss per share (improved from JP¥8.14 loss in 1Q 2022). Revenue: JP¥262.0m (up 51% from 1Q 2022). Net loss: JP¥17.0m (loss narrowed 65% from 1Q 2022).お知らせ • Nov 12Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023Human Metabolome Technologies, Inc. provided consolidated earnings guidance for the year ending June 2023. For the year, the company expects net sales of JPY 1,300 million, operating profit of JPY 240 million, profit attributable to owners of parent of JPY 270 million or JPY 45.76 per share basic.Valuation Update With 7 Day Price Move • Oct 31Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥828, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 16x in the Life Sciences industry in Japan. Negligible returns to shareholders over past three years.お知らせ • Sep 16Human Metabolome Technologies, Inc. to Report Q1, 2023 Results on Nov 11, 2022Human Metabolome Technologies, Inc. announced that they will report Q1, 2023 results on Nov 11, 2022Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥959, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 17x in the Life Sciences industry in Japan. Total returns to shareholders of 17% over the past three years.Reported Earnings • Aug 12Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: JP¥45.25 (up from JP¥9.84 in FY 2021). Revenue: JP¥1.22b (up 8.8% from FY 2021). Net income: JP¥267.0m (up 360% from FY 2021). Profit margin: 22% (up from 5.2% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 79%. Over the next year, revenue is forecast to grow 6.3%, compared to a 16% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 152% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Aug 12Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022.お知らせ • Jul 30Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC EquityHuman Metabolome Technologies, Inc. Common Stock will be deleted from OTC Equity effective from July 29, 2022, due to Inactive Security.Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥864, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 18x in the Life Sciences industry in Japan. Total loss to shareholders of 23% over the past three years.お知らせ • Jun 24Human Metabolome Technologies, Inc. to Report Fiscal Year 2022 Results on Aug 10, 2022Human Metabolome Technologies, Inc. announced that they will report fiscal year 2022 results on Aug 10, 2022Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥720, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 17x in the Life Sciences industry in Japan. Total loss to shareholders of 22% over the past three years.Reported Earnings • May 19Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: EPS: JP¥33.73 (up from JP¥16.96 in 3Q 2021). Revenue: JP¥477.0m (up 23% from 3Q 2021). Net income: JP¥199.0m (up 99% from 3Q 2021). Profit margin: 42% (up from 26% in 3Q 2021). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates by 16%. Over the next year, revenue is forecast to grow 5.6% compared to a 3.2% decline forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 138% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • May 15Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022Human Metabolome Technologies, Inc. provided earnings guidance for the full year ending June 2022. For the period, the company expected net sales of JPY 1,200 million, operating profit of JPY 150 million, profit attributable to owners of parent of JPY 170 million and basic earnings per share of JPY 28.81.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Junichi Matsuda was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 08Human Metabolome Technologies, Inc. to Report Q3, 2022 Results on May 13, 2022Human Metabolome Technologies, Inc. announced that they will report Q3, 2022 results on May 13, 2022Reported Earnings • Feb 17Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: EPS: JP¥22.03 (up from JP¥4.92 in 2Q 2021). Revenue: JP¥360.0m (up 23% from 2Q 2021). Net income: JP¥130.0m (up 348% from 2Q 2021). Profit margin: 36% (up from 9.9% in 2Q 2021). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates by 16%. Over the next year, revenue is forecast to grow 12% while the industry in Japan is not expected to grow. Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • Feb 16Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022Human Metabolome Technologies, Inc. provided consolidated earnings guidance for the year ending June 30, 2022. For the year ending June 30, 2022, the company expects consolidated net sales to be JPY 1,200 million, operating profit to be JPY 120 million, profit attributable to owners of parent to be JPY 120 million and basic earnings per share to be JPY 20.34.Reported Earnings • Nov 15First quarter 2022 earnings released: JP¥8.14 loss per share (vs JP¥6.11 loss in 1Q 2021)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2022 results: Revenue: JP¥173.0m (down 29% from 1Q 2021). Net loss: JP¥48.0m (loss widened 33% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.Reported Earnings • May 15Third quarter 2021 earnings released: EPS JP¥16.96 (vs JP¥22.98 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥389.0m (up 211% from 3Q 2020). Net income: JP¥100.0m (up JP¥235.0m from 3Q 2020). Profit margin: 26% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 14Second quarter 2021 earnings released: EPS JP¥4.92 (vs JP¥22.98 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥292.0m (up 134% from 2Q 2020). Net income: JP¥29.0m (up JP¥164.0m from 2Q 2020). Profit margin: 9.9% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 26New 90-day high: JP¥999The company is up 1.0% from its price of JP¥989 on 28 October 2020. The Japanese market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 2.0% over the same period.お知らせ • Dec 26Human Metabolome Technologies, Inc. to Report Q2, 2021 Results on Feb 12, 2021Human Metabolome Technologies, Inc. announced that they will report Q2, 2021 results on Feb 12, 2021Is New 90 Day High Low • Dec 17New 90-day low: JP¥741The company is down 37% from its price of JP¥1,170 on 18 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 16% over the same period.Is New 90 Day High Low • Dec 01New 90-day low: JP¥860The company is down 25% from its price of JP¥1,149 on 02 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 7.0% over the same period.お知らせ • Sep 26Human Metabolome Technologies, Inc. to Report Q1, 2021 Results on Nov 11, 2020Human Metabolome Technologies, Inc. announced that they will report Q1, 2021 results on Nov 11, 2020お知らせ • Jun 29Human Metabolome Technologies, Inc. to Report Fiscal Year 2020 Results on Aug 14, 2020Human Metabolome Technologies, Inc. announced that they will report fiscal year 2020 results on Aug 14, 2020株主還元6090JP Life SciencesJP 市場7D-0.5%-3.8%-2.5%1Y-24.1%-19.6%34.6%株主還元を見る業界別リターン: 6090過去 1 年間で-19.6 % の収益を上げたJP Life Sciences業界を下回りました。リターン対市場: 6090は、過去 1 年間で34.6 % のリターンを上げたJP市場を下回りました。価格変動Is 6090's price volatile compared to industry and market?6090 volatility6090 Average Weekly Movement4.3%Life Sciences Industry Average Movement6.1%Market Average Movement4.4%10% most volatile stocks in JP Market9.5%10% least volatile stocks in JP Market2.2%安定した株価: 6090 、 JP市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 6090の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200362Yasuhiro Ohatawww.humanmetabolome.comバイオテクノロジー企業ヒューマン・メタボローム・テクノロジーズ株式会社は、日本における創薬、診断、食品製造のためのメタボロミクス技術とソリューションの開発を行っています。メタボローム解析サービス、グローバルプロファイリング、ターゲットアッセイ、フラックス解析、リピドミクスサービスを提供。また、大うつ病性障害のバイオマーカーであり、血漿中で測定されるホスホリルエタノールアミンなどのバイオマーカーの開発も行っている。同社は、がん代謝、代謝フラックス分析、感染症、基礎科学、前臨床および臨床、食品および栄養、マイクロバイオームアプリケーション向けのソリューションを提供している。ヒューマン・メタボローム・テクノロジーズ社は、メタボローム解析技術の開発において、先端生命科学研究所および慶應義塾大学と共同研究を行っている。同社は2003年に設立され、鶴岡市に本社を置いている。もっと見るHuman Metabolome Technologies, Inc. 基礎のまとめHuman Metabolome Technologies の収益と売上を時価総額と比較するとどうか。6090 基礎統計学時価総額JP¥3.29b収益（TTM）JP¥117.00m売上高(TTM)JP¥1.30b28.1xPER（株価収益率2.5xP/Sレシオ6090 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6090 損益計算書（TTM）収益JP¥1.30b売上原価JP¥521.00m売上総利益JP¥775.00mその他の費用JP¥658.00m収益JP¥117.00m直近の収益報告Mar 31, 2026次回決算日Aug 07, 2026一株当たり利益（EPS）21.03グロス・マージン59.80%純利益率9.03%有利子負債／自己資本比率5.3%6090 の長期的なパフォーマンスは？過去の実績と比較を見る配当金3.0%現在の配当利回り73%配当性向6090 配当は確実ですか？6090 配当履歴とベンチマークを見る6090 、いつまでに購入すれば配当金を受け取れますか？Human Metabolome Technologies 配当日配当落ち日Jun 29 2026配当支払日Sep 04 2026配当落ちまでの日数37 days配当支払日までの日数30 days6090 配当は確実ですか？6090 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/04 16:39終値2026/08/04 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Human Metabolome Technologies, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Kiyokazu YamazakiIchiyoshi Research Institute Inc.
Upcoming Dividend • Jun 22Upcoming dividend of JP¥18.00 per shareEligible shareholders must have bought the stock before 29 June 2026. Payment date: 04 September 2026. Payout ratio is a comfortable 73% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.9%). Lower than average of industry peers (3.9%).
お知らせ • Jun 13Human Metabolome Technologies, Inc. to Report Fiscal Year 2026 Results on Aug 07, 2026Human Metabolome Technologies, Inc. announced that they will report fiscal year 2026 results on Aug 07, 2026
Reported Earnings • May 17Third quarter 2026 earnings released: EPS: JP¥21.76 (vs JP¥35.84 in 3Q 2025)Third quarter 2026 results: EPS: JP¥21.76 (down from JP¥35.84 in 3Q 2025). Revenue: JP¥448.0m (down 23% from 3Q 2025). Net income: JP¥122.0m (down 42% from 3Q 2025). Profit margin: 27% (down from 36% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
New Risk • Feb 16New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Dividend per share is over 5x cash flows per share. Dividend yield: 2.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Dividend is not well covered by cash flows (dividend per share is over 5x cash flows per share). Market cap is less than US$100m (JP¥4.28b market cap, or US$27.9m).
Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥24.79 (vs JP¥21.63 in 2Q 2025)Second quarter 2026 results: EPS: JP¥24.79 (up from JP¥21.63 in 2Q 2025). Revenue: JP¥467.0m (up 14% from 2Q 2025). Net income: JP¥140.0m (up 9.4% from 2Q 2025). Profit margin: 30% (down from 31% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.
Declared Dividend • Feb 14Dividend of JP¥18.00 announcedShareholders will receive a dividend of JP¥18.00. Ex-date: 29th June 2026 Payment date: 4th September 2026 Dividend yield will be 2.5%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 27% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Upcoming Dividend • Jun 22Upcoming dividend of JP¥18.00 per shareEligible shareholders must have bought the stock before 29 June 2026. Payment date: 04 September 2026. Payout ratio is a comfortable 73% but the company is paying out more than the cash it is generating. Trailing yield: 2.7%. Lower than top quartile of Japanese dividend payers (3.9%). Lower than average of industry peers (3.9%).
お知らせ • Jun 13Human Metabolome Technologies, Inc. to Report Fiscal Year 2026 Results on Aug 07, 2026Human Metabolome Technologies, Inc. announced that they will report fiscal year 2026 results on Aug 07, 2026
Reported Earnings • May 17Third quarter 2026 earnings released: EPS: JP¥21.76 (vs JP¥35.84 in 3Q 2025)Third quarter 2026 results: EPS: JP¥21.76 (down from JP¥35.84 in 3Q 2025). Revenue: JP¥448.0m (down 23% from 3Q 2025). Net income: JP¥122.0m (down 42% from 3Q 2025). Profit margin: 27% (down from 36% in 3Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
New Risk • Feb 16New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. Dividend per share is over 5x cash flows per share. Dividend yield: 2.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Dividend is not well covered by cash flows (dividend per share is over 5x cash flows per share). Market cap is less than US$100m (JP¥4.28b market cap, or US$27.9m).
Reported Earnings • Feb 14Second quarter 2026 earnings released: EPS: JP¥24.79 (vs JP¥21.63 in 2Q 2025)Second quarter 2026 results: EPS: JP¥24.79 (up from JP¥21.63 in 2Q 2025). Revenue: JP¥467.0m (up 14% from 2Q 2025). Net income: JP¥140.0m (up 9.4% from 2Q 2025). Profit margin: 30% (down from 31% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 1% per year.
Declared Dividend • Feb 14Dividend of JP¥18.00 announcedShareholders will receive a dividend of JP¥18.00. Ex-date: 29th June 2026 Payment date: 4th September 2026 Dividend yield will be 2.5%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased by an average of 6.3% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 27% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Feb 12Human Metabolome Technologies, Inc. (TSE:6090) announces an Equity Buyback for 25,000 shares, representing 4.44% for ¥200 million.Human Metabolome Technologies, Inc. (TSE:6090) announces a share repurchase program. Under the program, the company will repurchase up to 25,000 shares, representing 4.44% of its issued share capital, for ¥200 million. The purpose of the program is to improve shareholder returns and capital efficiency. The program will expire on December 31, 2026. As of December 31, 2025, the company had 5,627,579 shares in issue (excluding treasury stock and 292,218 shares in treasury.
お知らせ • Nov 29Human Metabolome Technologies, Inc. to Report Q2, 2026 Results on Feb 12, 2026Human Metabolome Technologies, Inc. announced that they will report Q2, 2026 results on Feb 12, 2026
New Risk • Nov 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (JP¥3.74b market cap, or US$24.2m).
Reported Earnings • Nov 15First quarter 2026 earnings released: JP¥17.08 loss per share (vs JP¥5.92 loss in 1Q 2025)First quarter 2026 results: JP¥17.08 loss per share (further deteriorated from JP¥5.92 loss in 1Q 2025). Revenue: JP¥192.0m (down 30% from 1Q 2025). Net loss: JP¥97.0m (loss widened 177% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has fallen by 4% per year.
お知らせ • Oct 02Human Metabolome Technologies, Inc. to Report Q1, 2026 Results on Nov 12, 2025Human Metabolome Technologies, Inc. announced that they will report Q1, 2026 results on Nov 12, 2025
分析記事 • Aug 16We Think That There Are Some Issues For Human Metabolome Technologies (TSE:6090) Beyond Its Promising EarningsHuman Metabolome Technologies, Inc.'s ( TSE:6090 ) healthy profit numbers didn't contain any surprises for investors...
Reported Earnings • Aug 10Full year 2025 earnings released: EPS: JP¥43.59 (vs JP¥41.10 in FY 2024)Full year 2025 results: EPS: JP¥43.59 (up from JP¥41.10 in FY 2024). Revenue: JP¥1.46b (up 8.2% from FY 2024). Net income: JP¥256.0m (up 5.3% from FY 2024). Profit margin: 18% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 2% per year.
お知らせ • Aug 08Human Metabolome Technologies, Inc., Annual General Meeting, Sep 19, 2025Human Metabolome Technologies, Inc., Annual General Meeting, Sep 19, 2025.
New Risk • Jul 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Market cap is less than US$100m (JP¥4.36b market cap, or US$29.3m).
Upcoming Dividend • Jun 20Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 27 June 2025. Payment date: 05 September 2025. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Japanese dividend payers (4.0%). Lower than average of industry peers (3.0%).
お知らせ • Jun 07Human Metabolome Technologies, Inc. to Report Fiscal Year 2025 Results on Aug 08, 2025Human Metabolome Technologies, Inc. announced that they will report fiscal year 2025 results on Aug 08, 2025
Reported Earnings • May 19Third quarter 2025 earnings released: EPS: JP¥35.84 (vs JP¥26.54 in 3Q 2024)Third quarter 2025 results: EPS: JP¥35.84 (up from JP¥26.54 in 3Q 2024). Revenue: JP¥582.0m (up 21% from 3Q 2024). Net income: JP¥211.0m (up 34% from 3Q 2024). Profit margin: 36% (up from 33% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year.
分析記事 • Apr 14Why Investors Shouldn't Be Surprised By Human Metabolome Technologies, Inc.'s (TSE:6090) P/EHuman Metabolome Technologies, Inc.'s ( TSE:6090 ) price-to-earnings (or "P/E") ratio of 15x might make it look like a...
お知らせ • Mar 01Human Metabolome Technologies, Inc. to Report Q3, 2025 Results on May 14, 2025Human Metabolome Technologies, Inc. announced that they will report Q3, 2025 results on May 14, 2025
Declared Dividend • Feb 15Dividend of JP¥15.00 announcedShareholders will receive a dividend of JP¥15.00. Ex-date: 27th June 2025 Payment date: 5th September 2025 Dividend yield will be 2.3%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 38% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Feb 13Human Metabolome Technologies, Inc. (TSE:6090) announces an Equity Buyback for 130,000 shares, representing 2.2% for ¥100 million.Human Metabolome Technologies, Inc. (TSE:6090) announces a share repurchase program. Under the program, the company will repurchase up to 130,000 shares, representing 2.2% of its issued share capital, for ¥100 million. The purpose of the program is to improve shareholder returns and capital efficiency. The program will expire on December 31, 2025. As of December 31, 2024, the company had 5,919,653 shares in issue (excluding treasury stock and 144 shares in treasury.
お知らせ • Jan 17Human Metabolome Technologies, Inc. to Report Q2, 2025 Results on Feb 13, 2025Human Metabolome Technologies, Inc. announced that they will report Q2, 2025 results on Feb 13, 2025
Board Change • Oct 07Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Natsukari Hajime was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Oct 03Human Metabolome Technologies' (TSE:6090) Weak Earnings May Only Reveal A Part Of The Whole PictureThe subdued market reaction suggests that Human Metabolome Technologies, Inc.'s ( TSE:6090 ) recent earnings didn't...
お知らせ • Oct 02Human Metabolome Technologies, Inc. to Report Q1, 2025 Results on Nov 13, 2024Human Metabolome Technologies, Inc. announced that they will report Q1, 2025 results on Nov 13, 2024
お知らせ • Aug 09Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024.
分析記事 • Aug 06Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The MarketWhen close to half the companies in Japan have price-to-earnings ratios (or "P/E's") above 14x, you may consider Human...
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to JP¥511, the stock trades at a trailing P/E ratio of 10.6x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total loss to shareholders of 32% over the past three years.
Buy Or Sell Opportunity • Aug 05Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to JP¥511. The fair value is estimated to be JP¥639, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Meanwhile, the company has become profitable.
Upcoming Dividend • Jun 20Upcoming dividend of JP¥15.00 per shareEligible shareholders must have bought the stock before 27 June 2024. Payment date: 09 September 2024. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (2.6%).
分析記事 • Jun 07Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00Human Metabolome Technologies, Inc.'s ( TSE:6090 ) dividend will be increasing from last year's payment of the same...
お知らせ • Jun 06Human Metabolome Technologies, Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024Human Metabolome Technologies, Inc. announced that they will report fiscal year 2024 results on Aug 09, 2024
分析記事 • May 22Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00Human Metabolome Technologies, Inc. ( TSE:6090 ) has announced that it will be increasing its dividend from last year's...
Reported Earnings • May 21Third quarter 2024 earnings released: EPS: JP¥26.54 (vs JP¥26.07 in 3Q 2023)Third quarter 2024 results: EPS: JP¥26.54 (up from JP¥26.07 in 3Q 2023). Revenue: JP¥483.0m (up 3.9% from 3Q 2023). Net income: JP¥157.0m (up 1.9% from 3Q 2023). Profit margin: 33% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
分析記事 • Apr 06Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last YearThe board of Human Metabolome Technologies, Inc. ( TSE:6090 ) has announced that it will be paying its dividend of...
お知らせ • Mar 28Human Metabolome Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024Human Metabolome Technologies, Inc. announced that they will report Q3, 2024 results on May 15, 2024
分析記事 • Mar 23Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00The board of Human Metabolome Technologies, Inc. ( TSE:6090 ) has announced that it will be paying its dividend of...
分析記事 • Feb 26Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00The board of Human Metabolome Technologies, Inc. ( TSE:6090 ) has announced that it will be paying its dividend of...
Reported Earnings • Feb 17Second quarter 2024 earnings released: EPS: JP¥18.43 (vs JP¥15.41 in 2Q 2023)Second quarter 2024 results: EPS: JP¥18.43 (up from JP¥15.41 in 2Q 2023). Revenue: JP¥397.0m (up 14% from 2Q 2023). Net income: JP¥109.0m (up 20% from 2Q 2023). Profit margin: 28% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Declared Dividend • Feb 16Dividend of JP¥15.00 announcedShareholders will receive a dividend of JP¥15.00. Ex-date: 27th June 2024 Payment date: 9th September 2024 Dividend yield will be 2.3%, which is higher than the industry average of 2.1%. Sustainability & Growth Dividend is covered by both earnings (22% earnings payout ratio) and cash flows (53% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 71% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
お知らせ • Nov 27Human Metabolome Technologies, Inc. to Report Q2, 2024 Results on Feb 14, 2024Human Metabolome Technologies, Inc. announced that they will report Q2, 2024 results on Feb 14, 2024
Reported Earnings • Nov 12First quarter 2024 earnings released: JP¥6.43 loss per share (vs JP¥2.88 loss in 1Q 2023)First quarter 2024 results: JP¥6.43 loss per share (further deteriorated from JP¥2.88 loss in 1Q 2023). Revenue: JP¥235.0m (down 10% from 1Q 2023). Net loss: JP¥38.0m (loss widened 124% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Sep 28Human Metabolome Technologies, Inc. to Report Q1, 2024 Final Results on Nov 10, 2023Human Metabolome Technologies, Inc. announced that they will report Q1, 2024 final results on Nov 10, 2023
New Risk • Aug 16New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 47% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (47% accrual ratio). Minor Risk Market cap is less than US$100m (JP¥4.29b market cap, or US$29.5m).
Reported Earnings • Aug 12Full year 2023 earnings released: EPS: JP¥48.27 (vs JP¥45.25 in FY 2022)Full year 2023 results: EPS: JP¥48.27 (up from JP¥45.25 in FY 2022). Revenue: JP¥1.30b (up 6.2% from FY 2022). Net income: JP¥285.0m (up 6.7% from FY 2022). Profit margin: 22% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
お知らせ • Aug 12Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023.
お知らせ • Jun 03Human Metabolome Technologies, Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023Human Metabolome Technologies, Inc. announced that they will report fiscal year 2023 results on Aug 10, 2023
Reported Earnings • May 17Third quarter 2023 earnings released: EPS: JP¥26.07 (vs JP¥33.73 in 3Q 2022)Third quarter 2023 results: EPS: JP¥26.07 (down from JP¥33.73 in 3Q 2022). Revenue: JP¥465.0m (down 2.5% from 3Q 2022). Net income: JP¥154.0m (down 23% from 3Q 2022). Profit margin: 33% (down from 42% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 18Second quarter 2023 earnings released: EPS: JP¥15.41 (vs JP¥22.03 in 2Q 2022)Second quarter 2023 results: EPS: JP¥15.41 (down from JP¥22.03 in 2Q 2022). Revenue: JP¥348.0m (down 3.3% from 2Q 2022). Net income: JP¥91.0m (down 30% from 2Q 2022). Profit margin: 26% (down from 36% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Dec 24Human Metabolome Technologies, Inc. to Report Q2, 2023 Results on Feb 14, 2023Human Metabolome Technologies, Inc. announced that they will report Q2, 2023 results on Feb 14, 2023
Buying Opportunity • Dec 20Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 26%. The fair value is estimated to be JP¥833, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last year. Meanwhile, the company has become profitable.
Reported Earnings • Nov 16First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)First quarter 2023 results: JP¥2.88 loss per share (improved from JP¥8.14 loss in 1Q 2022). Revenue: JP¥262.0m (up 51% from 1Q 2022). Net loss: JP¥17.0m (loss narrowed 65% from 1Q 2022).
Reported Earnings • Nov 13First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)First quarter 2023 results: JP¥2.88 loss per share (improved from JP¥8.14 loss in 1Q 2022). Revenue: JP¥262.0m (up 51% from 1Q 2022). Net loss: JP¥17.0m (loss narrowed 65% from 1Q 2022).
お知らせ • Nov 12Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023Human Metabolome Technologies, Inc. provided consolidated earnings guidance for the year ending June 2023. For the year, the company expects net sales of JPY 1,300 million, operating profit of JPY 240 million, profit attributable to owners of parent of JPY 270 million or JPY 45.76 per share basic.
Valuation Update With 7 Day Price Move • Oct 31Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥828, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 16x in the Life Sciences industry in Japan. Negligible returns to shareholders over past three years.
お知らせ • Sep 16Human Metabolome Technologies, Inc. to Report Q1, 2023 Results on Nov 11, 2022Human Metabolome Technologies, Inc. announced that they will report Q1, 2023 results on Nov 11, 2022
Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥959, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 17x in the Life Sciences industry in Japan. Total returns to shareholders of 17% over the past three years.
Reported Earnings • Aug 12Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: EPS: JP¥45.25 (up from JP¥9.84 in FY 2021). Revenue: JP¥1.22b (up 8.8% from FY 2021). Net income: JP¥267.0m (up 360% from FY 2021). Profit margin: 22% (up from 5.2% in FY 2021). The increase in margin was primarily driven by lower expenses. Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 79%. Over the next year, revenue is forecast to grow 6.3%, compared to a 16% growth forecast for the pharmaceuticals industry in Japan. Over the last 3 years on average, earnings per share has increased by 152% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Aug 12Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022.
お知らせ • Jul 30Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC EquityHuman Metabolome Technologies, Inc. Common Stock will be deleted from OTC Equity effective from July 29, 2022, due to Inactive Security.
Valuation Update With 7 Day Price Move • Jul 14Investor sentiment improved over the past weekAfter last week's 16% share price gain to JP¥864, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 18x in the Life Sciences industry in Japan. Total loss to shareholders of 23% over the past three years.
お知らせ • Jun 24Human Metabolome Technologies, Inc. to Report Fiscal Year 2022 Results on Aug 10, 2022Human Metabolome Technologies, Inc. announced that they will report fiscal year 2022 results on Aug 10, 2022
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥720, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 17x in the Life Sciences industry in Japan. Total loss to shareholders of 22% over the past three years.
Reported Earnings • May 19Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: EPS: JP¥33.73 (up from JP¥16.96 in 3Q 2021). Revenue: JP¥477.0m (up 23% from 3Q 2021). Net income: JP¥199.0m (up 99% from 3Q 2021). Profit margin: 42% (up from 26% in 3Q 2021). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates by 16%. Over the next year, revenue is forecast to grow 5.6% compared to a 3.2% decline forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 138% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • May 15Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022Human Metabolome Technologies, Inc. provided earnings guidance for the full year ending June 2022. For the period, the company expected net sales of JPY 1,200 million, operating profit of JPY 150 million, profit attributable to owners of parent of JPY 170 million and basic earnings per share of JPY 28.81.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Director Junichi Matsuda was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 08Human Metabolome Technologies, Inc. to Report Q3, 2022 Results on May 13, 2022Human Metabolome Technologies, Inc. announced that they will report Q3, 2022 results on May 13, 2022
Reported Earnings • Feb 17Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: EPS: JP¥22.03 (up from JP¥4.92 in 2Q 2021). Revenue: JP¥360.0m (up 23% from 2Q 2021). Net income: JP¥130.0m (up 348% from 2Q 2021). Profit margin: 36% (up from 9.9% in 2Q 2021). The increase in margin was primarily driven by higher revenue. Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates by 16%. Over the next year, revenue is forecast to grow 12% while the industry in Japan is not expected to grow. Over the last 3 years on average, earnings per share has increased by 117% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • Feb 16Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022Human Metabolome Technologies, Inc. provided consolidated earnings guidance for the year ending June 30, 2022. For the year ending June 30, 2022, the company expects consolidated net sales to be JPY 1,200 million, operating profit to be JPY 120 million, profit attributable to owners of parent to be JPY 120 million and basic earnings per share to be JPY 20.34.
Reported Earnings • Nov 15First quarter 2022 earnings released: JP¥8.14 loss per share (vs JP¥6.11 loss in 1Q 2021)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2022 results: Revenue: JP¥173.0m (down 29% from 1Q 2021). Net loss: JP¥48.0m (loss widened 33% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
Reported Earnings • May 15Third quarter 2021 earnings released: EPS JP¥16.96 (vs JP¥22.98 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥389.0m (up 211% from 3Q 2020). Net income: JP¥100.0m (up JP¥235.0m from 3Q 2020). Profit margin: 26% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 14Second quarter 2021 earnings released: EPS JP¥4.92 (vs JP¥22.98 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥292.0m (up 134% from 2Q 2020). Net income: JP¥29.0m (up JP¥164.0m from 2Q 2020). Profit margin: 9.9% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 26New 90-day high: JP¥999The company is up 1.0% from its price of JP¥989 on 28 October 2020. The Japanese market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 2.0% over the same period.
お知らせ • Dec 26Human Metabolome Technologies, Inc. to Report Q2, 2021 Results on Feb 12, 2021Human Metabolome Technologies, Inc. announced that they will report Q2, 2021 results on Feb 12, 2021
Is New 90 Day High Low • Dec 17New 90-day low: JP¥741The company is down 37% from its price of JP¥1,170 on 18 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 16% over the same period.
Is New 90 Day High Low • Dec 01New 90-day low: JP¥860The company is down 25% from its price of JP¥1,149 on 02 September 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 7.0% over the same period.
お知らせ • Sep 26Human Metabolome Technologies, Inc. to Report Q1, 2021 Results on Nov 11, 2020Human Metabolome Technologies, Inc. announced that they will report Q1, 2021 results on Nov 11, 2020
お知らせ • Jun 29Human Metabolome Technologies, Inc. to Report Fiscal Year 2020 Results on Aug 14, 2020Human Metabolome Technologies, Inc. announced that they will report fiscal year 2020 results on Aug 14, 2020
